Efficacy and safety of pemafibrate in people with type 2 diabetes and elevated triglyceride levels: 52‐week data from the PROVIDE study

The aim of this study was to evaluate the efficacy and safety of pemafibrate in people with type 2 diabetes and hypertriglyceridaemia over a 52‐week period. Participants were randomly assigned to receive treatment with placebo or pemafibrate at a dose of 0.2 or 0.4 mg/d for 24 weeks (treatment perio...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Diabetes Obes Metab
Autori principali: Araki, Eiichi, Yamashita, Shizuya, Arai, Hidenori, Yokote, Koutaro, Satoh, Jo, Inoguchi, Toyoshi, Nakamura, Jiro, Maegawa, Hiroshi, Yoshioka, Narihito, Tanizawa, Yukio, Watada, Hirotaka, Suganami, Hideki, Ishibashi, Shun
Natura: Artigo
Lingua:Inglês
Pubblicazione: Blackwell Publishing Ltd 2019
Soggetti:
Brief Reports
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6617746/
https://ncbi.nlm.nih.gov/pubmed/30830727
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.13686
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi